Bordetella Infections is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Bordetella Infections have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Bordetella Infections compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Bordetella Infections overview
Bordetella infections are respiratory diseases caused by bacteria of the genus Bordetella. They can affect humans and other mammals, especially children, sheep, dogs and pigs. The most common and serious Bordetella infection in humans is pertussis, also known as whooping cough. It is characterized by severe coughing spells, fever, runny nose and sometimes vomiting and pneumonia. Pertussis is highly contagious and can be spread through droplets from coughing or sneezing. It can be prevented by vaccination and treated by antibiotics. Other Bordetella infections in humans include parapertussis, bronchiectasis and holmesii, which are usually milder than pertussis. Bordetella infections in animals can cause similar respiratory symptoms and may be transmitted to humans by inhalation of infected aerosols.
For a complete picture of PTSR and LoA scores for drugs in Bordetella Infections, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.